{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:36:46Z","timestamp":1792773406774,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jfo.2026.105010","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:34:21Z","timestamp":1792766061000},"page":"105010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Suprachoroidal triamcinolone acetonide for macular edema: A systematic review of efficacy and safety"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4784-6660","authenticated-orcid":false,"given":"M.H.","family":"Hedhiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0555-8793","authenticated-orcid":false,"given":"Y.","family":"Oueslati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lajmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Laajimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9692-7120","authenticated-orcid":false,"given":"S.","family":"Mbarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Messaoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2026.105010_bib0125","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ophtha.2018.04.007","article-title":"Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings","volume":"125","author":"Wong","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2026.105010_bib0130","doi-asserted-by":"crossref","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","article-title":"Diabetic retinopathy preferred practice Pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2026.105010_bib0135","doi-asserted-by":"crossref","first-page":"1695.e1","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2026.105010_bib0140","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.preteyeres.2005.01.004","article-title":"Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases","volume":"24","author":"Jonas","year":"2005","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jfo.2026.105010_bib0145","doi-asserted-by":"crossref","first-page":"435","DOI":"10.4155\/tde.10.40","article-title":"Recent advances in ophthalmic drug delivery","volume":"1","author":"Kompella","year":"2010","journal-title":"Ther Deliv"},{"key":"10.1016\/j.jfo.2026.105010_bib0150","first-page":"233","article-title":"Hydrostatic pressure of the suprachoroidal space","volume":"30","author":"Emi","year":"1989","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2026.105010_bib0155","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ajo.2006.05.045","article-title":"Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment","volume":"142","author":"Olsen","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105010_bib0160","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","article-title":"Suprachoroidal drug delivery to the back of the eye using hollow microneedles","volume":"28","author":"Patel","year":"2011","journal-title":"Pharm Res"},{"key":"10.1016\/j.jfo.2026.105010_bib0165","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1167\/iovs.12-9872","article-title":"Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye","volume":"53","author":"Patel","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2026.105010_bib0170","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1097\/IAE.0000000000002279","article-title":"Suprachoroidal injection of triamcinolone acetonide, CLS-TA, for macular edema due to noninfectious uveitis: a randomized, phase 2 study (DOGWOOD)","volume":"39","author":"Yeh","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2026.105010_bib0175","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40123-022-00603-x","article-title":"Triamcinolone acetonide suprachoroidal injectable suspension for uveitic macular edema: integrated analysis of two phase 3 studies","volume":"12","author":"Yeh","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jfo.2026.105010_bib0180","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/bjophthalmol-2020-318019","article-title":"Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA)","volume":"106","author":"Henry","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105010_bib0185","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12886-023-02790-y","article-title":"Suprachoroidal injection of triamcinolone acetonide plus intravitreal bevacizumab in diabetic macular edema: a randomized pilot trial","volume":"23","author":"Fazel","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105010_bib0190","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2147\/OPTH.S351853","article-title":"Suprachoroidal versus intravitreal triamcinolone acetonide for the treatment of diabetic macular edema","volume":"16","author":"Zakaria","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105010_bib0195","doi-asserted-by":"crossref","first-page":"239","DOI":"10.47391\/JPMA.2239","article-title":"Suprachoroidal injection of triamcinolone acetonide for management of resistant diabetic macular oedema","volume":"73","author":"Ateeq","year":"2023","journal-title":"J Pak Med Assoc"},{"key":"10.1016\/j.jfo.2026.105010_bib0200","doi-asserted-by":"crossref","first-page":"7947710","DOI":"10.1155\/2022\/7947710","article-title":"A randomized trial comparing suprachoroidal and intravitreal injection of triamcinolone acetonide in refractory diabetic macular edema due to epiretinal membrane","volume":"2022","author":"Abdelshafy Tabl","year":"2022","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105010_bib0205","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.oret.2018.03.008","article-title":"Suprachoroidal triamcinolone acetonide for diabetic macular edema: The HULK trial","volume":"2","author":"Wykoff","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jfo.2026.105010_bib0210","first-page":"3501","article-title":"Suprachoroidal versus sub-Tenon triamcinolone acetonide in diabetic macular edema: a prospective comparative study","volume":"17","author":"Tharwat","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105010_bib0215","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.oret.2017.07.013","article-title":"Suprachoroidal triamcinolone acetonide for retinal vein occlusion: results of the tanzanite study","volume":"2","author":"Campochiaro","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jfo.2026.105010_bib0220","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2147\/OPTH.S361636","article-title":"Modified microneedle for suprachoroidal injection of triamcinolone acetonide combined with intravitreal injection of ranibizumab in branch retinal vein occlusion patients","volume":"16","author":"Nawar","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105010_bib0225","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3390\/pharmaceutics13070967","article-title":"Drug delivery via the suprachoroidal space for the treatment of retinal diseases","volume":"13","author":"Naftali Ben Haim","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jfo.2026.105010_bib0230","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12886-023-02808-5","article-title":"Suprachoroidal triamcinolone acetonide for the treatment of macular edema associated with retinal vein occlusion: a pilot study","volume":"23","author":"Ali","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jfo.2026.105010_bib0235","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema (MEAD study)","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2026.105010_bib0240","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","article-title":"Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema (FAME study)","volume":"119","author":"Campochiaro","year":"2012","journal-title":"Ophthalmology"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551226002366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551226002366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:05:32Z","timestamp":1792767932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551226002366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0181551226002366"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2026.105010","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suprachoroidal triamcinolone acetonide for macular edema: A systematic review of efficacy and safety","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2026.105010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105010"}}